OBJECTIVE: Ovarian cancer is the leading cause of death from gynecologic malignancies in the Western world. Fibroblast growth factor receptor (FGFR) signaling has been implicated to play a role in ovarian tumorigenesis. Mutational activation of one member of this receptor family, FGFR2, is a frequent event in endometrioid endometrial cancer. Given the similarities in the histologic and molecular genetics of ovarian and endometrial cancers, we hypothesized that activating FGFR2 mutations may occur in a subset of endometrioid ovarian tumors, and possibly other histotypes. METHODS: Six FGFR2 exons were sequenced in 120 primary ovarian tumors representing the major histologic subtypes. RESULTS: FGFR2 mutation was detected at low frequency in endometrioid (1/46, 2.2%) and serous (1/41, 2.4%) ovarian cancer. No mutations were detected in clear cell, mucinous, or mixed histology tumors or in the ovarian cancer cell lines tested. Functional characterization of the FGFR2 mutations confirmed that the mutations detected in ovarian cancer result in receptor activation. CONCLUSIONS: Despite the low incidence of FGFR2 mutations in ovarian cancer, the two FGFR2 mutations identified in ovarian tumors (S252W, Y376C) overlap with the oncogenic mutations previously identified in endometrial tumors, suggesting activated FGFR2 may contribute to ovarian cancer pathogenesis in a small subset of ovarian tumors. Copyright 2009 Elsevier Inc. All rights reserved.
OBJECTIVE:Ovarian cancer is the leading cause of death from gynecologic malignancies in the Western world. Fibroblast growth factor receptor (FGFR) signaling has been implicated to play a role in ovarian tumorigenesis. Mutational activation of one member of this receptor family, FGFR2, is a frequent event in endometrioid endometrial cancer. Given the similarities in the histologic and molecular genetics of ovarian and endometrial cancers, we hypothesized that activating FGFR2 mutations may occur in a subset of endometrioid ovarian tumors, and possibly other histotypes. METHODS: Six FGFR2 exons were sequenced in 120 primary ovarian tumors representing the major histologic subtypes. RESULTS:FGFR2 mutation was detected at low frequency in endometrioid (1/46, 2.2%) and serous (1/41, 2.4%) ovarian cancer. No mutations were detected in clear cell, mucinous, or mixed histology tumors or in the ovarian cancer cell lines tested. Functional characterization of the FGFR2 mutations confirmed that the mutations detected in ovarian cancer result in receptor activation. CONCLUSIONS: Despite the low incidence of FGFR2 mutations in ovarian cancer, the two FGFR2 mutations identified in ovarian tumors (S252W, Y376C) overlap with the oncogenic mutations previously identified in endometrial tumors, suggesting activated FGFR2 may contribute to ovarian cancer pathogenesis in a small subset of ovarian tumors. Copyright 2009 Elsevier Inc. All rights reserved.
Authors: Yvette W Jeske; Shamshad Ali; Sara A Byron; Feng Gao; Robert S Mannel; Rahel G Ghebre; Paul A DiSilvestro; Shashikant B Lele; Michael L Pearl; Amy P Schmidt; Heather A Lankes; Nilsa C Ramirez; Golnar Rasty; Matthew Powell; Paul J Goodfellow; Pamela M Pollock Journal: Gynecol Oncol Date: 2017-03-15 Impact factor: 5.482
Authors: Andrew Beenken; Anna V Eliseenkova; Omar A Ibrahimi; Shaun K Olsen; Moosa Mohammadi Journal: J Biol Chem Date: 2011-11-04 Impact factor: 5.157
Authors: Zhiyong Liu; Yolanda E Hartman; Jason M Warram; Joseph A Knowles; Larissa Sweeny; Tong Zhou; Eben L Rosenthal Journal: Mol Cancer Res Date: 2011-06-10 Impact factor: 5.852
Authors: Sara A Byron; Huaibin Chen; Andreas Wortmann; David Loch; Michael G Gartside; Farhad Dehkhoda; Steven P Blais; Thomas A Neubert; Moosa Mohammadi; Pamela M Pollock Journal: Neoplasia Date: 2013-08 Impact factor: 5.715
Authors: Philip J Stephens; Helen R Davies; Yoshitsugu Mitani; Peter Van Loo; Adam Shlien; Patrick S Tarpey; Elli Papaemmanuil; Angela Cheverton; Graham R Bignell; Adam P Butler; John Gamble; Stephen Gamble; Claire Hardy; Jonathan Hinton; Mingming Jia; Alagu Jayakumar; David Jones; Calli Latimer; Stuart McLaren; David J McBride; Andrew Menzies; Laura Mudie; Mark Maddison; Keiran Raine; Serena Nik-Zainal; Sarah O'Meara; Jon W Teague; Ignacio Varela; David C Wedge; Ian Whitmore; Scott M Lippman; Ultan McDermott; Michael R Stratton; Peter J Campbell; Adel K El-Naggar; P Andrew Futreal Journal: J Clin Invest Date: 2013-06-17 Impact factor: 14.808
Authors: Zamal Ahmed; Chi-Chuan Lin; Kin M Suen; Fernando A Melo; James A Levitt; Klaus Suhling; John E Ladbury Journal: J Cell Biol Date: 2013-02-18 Impact factor: 10.539